Glow-in-the-Dark endoscopy could predict immunotherapy success
NCT ID NCT07196384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new imaging method to see if immunotherapy targets (PD-1 and PD-L1 proteins) are present in esophageal cancer. About 15 participants will receive two fluorescent tracers before a routine endoscopic exam. The goal is to find out if this 'fluorescence endoscopy' can reliably detect these proteins, which may help doctors decide who will benefit from immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
- Can Real-World data improve esophageal cancer care in africa?
- Stent showdown: which esophageal prosthesis best restores swallowing in advanced cancer?
- DNA clues may reveal which esophageal cancers will return soon after surgery
- Can a condensed radiation blast plus chemo keep esophageal cancer at bay?